Global Proton Pump Inhibitors Market Is Estimated To Witness High Growth Owing To Growing Prevalence Of GERD

Proton Pump Inhibitors Market 

Proton pump inhibitors reduce the production of stomach acid by irreversibly blocking an enzyme called H+/K+ ATPase in parietal cells in the stomach. They are used to treat conditions caused by or exacerbated by excess stomach acid, such as gastroesophageal reflux disease (GERD), peptic ulcers, Barrett's esophagus, and Zollinger-Ellison syndrome, and to maintain healing of erosive esophagitis. PPIs are very effective and well tolerated, with few significant side effects and drug interactions.

Rising product launches are estimated to augment growth of the Proton Pump Inhibitors Market during the forecast period. For instance, Escorten, was launched by Daewon Pharmaceutical, in April 2022. Its proton-pump inhibitor (PPI) treatment is effective for addressing gastric mucosal lesions in chronic and acute gastritis in Korea. Moreover, rising use of generic products and increasing side effects associated with the drugs are anticipated to restrain growth of the global proton pump inhibitors market during the forecast period.

The Global Proton Pump Inhibitors Market Is Estimated To Be Valued At US$ 2.9 Billion In 2020 And Is Expected To Exhibit A CAGR Of 4.30% During The Forecast Period (2020-2027).

They are usually taken before meals to maximize their effectiveness as proton pumps become activated with food ingestion. However, long-term use of PPIs has been linked to an increased risk of hip fractures and a deficiency of magnesium in the blood. The most commonly used PPIs are omeprazole, lansoprazole, and rabeprazole. All of these medications have a similar activity, and they are available OTC and by prescription. They have a narrow therapeutic window, meaning that they are effective at very low dosages.

Market Dynamics:

The pandemic was first reported in Wuhan in 2019. This outbreak affected several countries globally. Many nations had to impose strict lockdowns for avoiding transmission of the virus. Countries like India, the US, China, Italy, UAE, and many more imposed strict restrictions for preventing spread of the virus. The pandemic also led to hampering production activities in many sectors such as automobiles, electronics and many more. The pandemic led to shortage of raw materials and other resources in several nations. This was also seen in the pharmaceutical sector as many companies were focusing on using their resources for developing vaccines and drugs for batting COVID-19. This had a negative impact on the growth of global Proton Pump Inhibitors Market. However, the market is estimated to witness growth in the post-pandemic era, as all restrictions were relaxed.

Key Takeaways:

The global proton pump inhibitors market is expected to witness high growth, exhibiting CAGR of 4.30 % over the forecast period, due to increasing research and developmental activities.  For instance, Omeprazole delayed-release capsules were launched by the generic division of Insud Pharmaceuticals, in March 2021. This is a cost-effective alternative for Prilosec®.

North America is anticipated to witness significant growth in the global Proton Pump Inhibitors Market during the forecast period, due to growing shift toward unhealthy lifestyles and rising prevalence of GERD in the US.